Key Takeaways:
(P1) Pharmaceutical giants Eli Lilly and Novo Nordisk are accelerating the global rollout of their oral GLP-1 obesity pills, intensifying the rivalry in a market projected to support $119 billion in annual sales for Lilly alone by 2030.
(P2) "About half of the surveyed physicians expect oral GLP-1 medications to bring new people into the drug class," analysts at Citigroup said in a note, highlighting that 74 percent of endocrinologists see the fasting requirements for Novo's oral Wegovy as a prescribing deterrent.
(P3) The survey findings bolster the case for Lilly's Foundayo, which has no food or water restrictions. Citigroup analysts now estimate Foundayo sales will hit $2.8 billion in 2026, nearly double the consensus expectation of $1.5 billion. Lilly's stock rose more than 2 percent on the news, trading at $1,012.27.
(P4) The strategic pivot to oral medications opens a new front in the battle for dominance in the weight-loss market. With Lilly's injectable Tirzepatide already leading, the company aims to capture a broader patient base, including those who have stopped or are hesitant to start injectable treatments.
The competition between Lilly’s Foundayo and Novo Nordisk’s oral version of Wegovy is becoming a key focus for investors. While Novo Nordisk had a first-mover advantage, the convenience of Lilly's drug appears to be a significant competitive edge. According to Lilly's late April earnings call, about 80 percent of Foundayo prescriptions are for patients new to the GLP-1 class, suggesting the pill is expanding the market rather than just converting existing users.
Wavelength Research projects that Foundayo could capture over $20 billion in sales by 2030, targeting the global maintenance and "Overweight" markets. This, combined with the injectable Tirzepatide and the next-generation Retatrutide, is expected to generate $119 billion in 2030 sales for Eli Lilly, driving an estimated 22.6 percent earnings per share compound annual growth rate.
The expanding use of GLP-1 drugs is also revealing significant cardiovascular benefits. A recent meta-analysis of 32 clinical trials involving over 43,000 adults found that modern obesity medications were linked to an average 5.2 mmHg reduction in systolic blood pressure. The study, presented at the European Congress on Obesity, found that every 1 percent reduction in body weight was associated with a 0.34 mmHg drop in systolic blood pressure.
"The magnitude of blood pressure lowering observed with some of these therapies approached that seen with standard antihypertensive medications," lead study author Dr. Marcel Muskiet said. This suggests that drugs like Foundayo and Wegovy could play a dual role in managing both obesity and hypertension, significantly broadening their clinical and commercial potential.
The accelerated global launch of oral GL-1 drugs signals a new phase of intense competition and market expansion. For investors, the focus will be on market share gains between Lilly's Foundayo and Novo's oral Wegovy, with upcoming quarterly reports providing key data on prescription trends and new patient adoption.
This article is for informational purposes only and does not constitute investment advice.
